Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Disease-modifying treatment

- PMLiVE

Artificial Intelligence: the new healthcare algorithm

The age of computers has hugely evolved, and with the emergence of effective machine learning, pattern recognition, and decision-making algorithms, Artificial Intelligence provides a revolutionary new approach to tailored healthcare....

Blue Latitude Health

Immuno-oncology; bringing patients closer to treatment

What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment?

Blue Latitude Health

- PMLiVE

Allergies and asthma

Reframing the conversation from disease burden to prevention and health promotion

- PMLiVE

European prostate cancer treatment is changing – what are the opportunities for marketers?

Consultant Jeremy Poland examines some of the key dynamics in prostate cancer multi-disciplinary teams across Europe and how the recent trends impact the opportunities available to healthcare marketers.

Blue Latitude Health

- PMLiVE

Focus on multiple myeloma treatment: Witnessing a transformation

Consultant David Cooney of Blue Latitude Health will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.

Blue Latitude Health

EU flag

EMA unveils draft guidelines for Alzheimer’s disease research

Puts plans for evaluating potential new therapies out for consultation

- PMLiVE

Glimmer of hope for amyloid drugs in Alzheimer’s?

Expectations remain high but high efficacy rates still allusive for most firms

- PMLiVE

AbbVie and C2N take tau antibody into clinic

Treatment being assessed for a progressive neurodegenerative disorder

- PMLiVE

Roche and Evotec’s Alzheimer’s drug ineffective

Sembragiline failed to show cognitive and memory benefits

- PMLiVE

Icelandic genome study yields new disease genes

Nature Medicine study focuses on the probability of developing Alzheimer’s

Biogen Idec building

Biogen Idec claims first with Alzheimer’s candidate

Aducanumab slowed down impairment in cognition and memory in early stages

- PMLiVE

Neurodegenerative research needs better cooperation, say GlobalData

And public funding must be provided to eradicate business risks

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links